Researchers at Johns Hopkins University believe that during their lifetimes, a "biological computer" that is driven by human brain cells will be produced. They anticipate that this technology would exponentially extend the capabilities of contemporary computers and open new fields of research. In an article published in the journal Frontiers of Science, the group described their goals for "organ-like intelligence".
According to Thomas Hartung, a professor of environmental health sciences at the Johns Hopkins Bloomberg School of Public Health and Whiting School of Engineering, "computers and artificial intelligence have been driving a technological revolution that is now peaking, and biocomputing is a huge effort to compress computing power and make it more efficient to push the limits of our current technology."
Scientists have been conducting studies on kidneys, lungs, and other organs without using human or animal subjects for over two decades using organoids—lab-cultured tissues that resemble fully developed organs. Recently, Hartung and his colleagues at Johns Hopkins have begun examining the organ resembling the brain, a pencil-sized sphere containing neurons and other traits that are believed to support fundamental activities like as learning and memory.
One such use is organ-on-a-chip, which uses microfluidics to simulate a functioning organ on a small scale. By employing micromachining techniques, researchers have been able to build a bionic system on a microfluidic chip that mimics the primary functions of human organs. In order to accurately mimic the complex structure, microenvironment, and physiological functions of human organs, organs-on-a-chip not only feature the miniaturization, integration, and low consumption of microfluidic technology, but also the ability to build cell graphics culture and realize the tissue-tissue and organ-organ interface interaction.
Hartung began using cells from human skin samples reprogrammed to an embryonic stem cell-like state in 2012 to culture and assemble brain cells into functional organoids. Each organoid contains about 50,000 cells, roughly the size of the fruit fly nervous system. He now envisions building a future computer from such brain-like organs.
Hartung stated that computers utilizing this "biological hardware" might begin to lower the unsustainable energy consumption requirements of supercomputing in the next decade. Although computers are quicker than humans in performing computations involving numbers and data, the brain is far more adept at making complicated logical judgments, such as distinguishing between dogs and cats.
According to Lena Smirnova, assistant professor of environmental health and engineering at Johns Hopkins University, organoid intelligence might also transform drug-testing research for neurodevelopmental disorders and neurodegeneration.
"We want to compare brain-like organs from normally developing donors with those from autistic donors, and the biocomputational tools currently being developed are the same tools that enable us to understand the neuronal network changes specific to autism without using animals or touching patients, so that we can understand why patients have these underlying mechanistic issues and cognitive impairments," said Smirnova. A varied consortium of scientists, bioethicists, and members of the public have been added to the team in order to evaluate the ethical implications of working with organoid intelligence.
According to the report published by Allied Market Research, the global biotech ingredients market was pegged at $51.3 billion in 2020 and is estimated to hit $75.3 billion by 2028, registering a CAGR of 4.8% from 2021 to 2028.
The report provides an in-depth analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and changing market trends.Shift in consumer preference from synthetic to bio-based ingredients and development in biotechnology fuel the growth of the global biotech ingredients market.
On the other hand, limited availability of raw materials restrains the growth to some extent.
However, favorable government policies and technological advancements in bio-engineering are expected to create lucrative opportunities in the industry.Request PDF Brochure: https://www.alliedmarketresearch.com/request-sample/11710COVID-19 scenario-The outbreak of the pandemic has given way to either closure or suspension of production activities in most industrial units across the globe, which has impacted the market negatively.Nevertheless, initiation of mass vaccination in most countries is projected to mend the global situation and market is expected to get back on track soon.The global biotech ingredients market is analyzed across type, product, expression systems, and region.
The biosimilars segment, on the other hand, would exhibit the fastest CAGR of 5.0% during the forecast period.Based on product, the monoclonal antibodies segment contributed to more than one-fifth of the total market revenue in 2020 and is expected to dominate by 2028.
However, the hormones and growth factors segment would cite the fastest CAGR of 5.5% during from 2021 to 2028.Get Detailed COVID-19 Impact Analysis on the Biotech Ingredients Market: https://www.alliedmarketresearch.com/request-for-customization/11710?reqfor=covidBased on region, Europe held the major share in 2020, garnering nearly two-fifths of the global market.
